Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.

Barbareschi M, Cuorvo LV, Girlando S, Bragantini E, Eccher C, Leonardi E, Ferro A, Caldara A, Triolo R, Cantaloni C, Decarli N, Galligioni E, Dalla Palma P.

Virchows Arch. 2012 Aug;461(2):129-39. doi: 10.1007/s00428-012-1267-2. Epub 2012 Jun 29.

PMID:
22744290
2.
3.

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.

Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19.

PMID:
21594665
4.

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.

Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA.

Clin Cancer Res. 2012 Dec 15;18(24):6784-91. doi: 10.1158/1078-0432.CCR-12-1785. Epub 2012 Oct 23.

5.

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC.

J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6.

6.

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X.

BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248.

7.
8.

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J.

Ann Oncol. 2015 Jul;26(7):1494-500. doi: 10.1093/annonc/mdv175. Epub 2015 Apr 7.

9.

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G.

Br J Cancer. 2012 Apr 10;106(8):1367-73. doi: 10.1038/bjc.2012.85. Epub 2012 Mar 27.

10.

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, Andersson M, Ewertz M.

Ann Oncol. 2012 Aug;23(8):2034-42. doi: 10.1093/annonc/mdr546. Epub 2011 Dec 15.

PMID:
22172323
11.

PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

Cuorvo LV, Verderio P, Ciniselli CM, Girlando S, Decarli N, Leonardi E, Ferro A, Caldara A, Triolo R, Eccher C, Cantaloni C, Mauri F, Seckl M, Volante M, Buttitta F, Marchetti A, Silvia Q, Galligioni E, Palma PD, Barbareschi M.

Virchows Arch. 2014 Jan;464(1):85-93.

PMID:
24233241
12.

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S.

Ann Oncol. 2009 Jan;20(1):84-90. doi: 10.1093/annonc/mdn541. Epub 2008 Jul 31.

PMID:
18669866
13.

An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.

Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Iwase H.

PLoS One. 2014 Dec 26;9(12):e116054. doi: 10.1371/journal.pone.0116054. eCollection 2014 Dec 26.

14.

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.

Du C, Yi X, Liu W, Han T, Liu Z, Ding Z, Zheng Z, Piao Y, Yuan J, Han Y, Xie M, Xie X.

BMC Cancer. 2014 Nov 24;14:869. doi: 10.1186/1471-2407-14-869.

15.

Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.

Adamczyk A, Niemiec J, Janecka A, Harazin-Lechowska A, Ambicka A, Grela-Wojewoda A, Domagała-Haduch M, Cedrych I, Majchrzyk K, Kruczak A, Ryś J, Jakubowicz J.

Pol J Pathol. 2015 Jun;66(2):133-41.

16.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.

Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2.

17.

PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.

Duman BB, Sahin B, Acikalin A, Ergin M, Zorludemir S.

J BUON. 2013 Jan-Mar;18(1):44-50.

PMID:
23613387
18.

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.

Elster N, Cremona M, Morgan C, Toomey S, Carr A, O'Grady A, Hennessy BT, Eustace AJ.

Breast Cancer Res Treat. 2015 Jan;149(2):373-83. doi: 10.1007/s10549-014-3239-5. Epub 2014 Dec 21.

PMID:
25528022
19.

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment.

Park YH, Jung HA, Choi MK, Chang W, Choi YL, Do IG, Ahn JS, Im YH.

Br J Cancer. 2014 Jan 21;110(2):384-91. doi: 10.1038/bjc.2013.757. Epub 2013 Dec 17.

20.

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L.

Ann Oncol. 2009 Apr;20(4):648-54. doi: 10.1093/annonc/mdn681. Epub 2009 Feb 2.

PMID:
19188134

Supplemental Content

Support Center